We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

MEDIX BIOCHEMICA AB

Develops, produces and markets monoclonal antibodies, antibody services and recombinant antigens for IVD industry, as... read more Featured Products: More products

Download Mobile App





Medix Biochemica Celebrates Launch of New Molecular Diagnostic Reagents Division at MEDICA 2021

By LabMedica International staff writers
Posted on 15 Nov 2021

Medix Biochemica (Espoo, Finland) celebrated the launch of its new molecular diagnostic reagents division, MedixMDx at this year's MEDICA, the world's largest annual medical technology trade fair, which took place from 15-18 November in Düsseldorf, Germany. More...

Medix, including Lee Biosolutions, EastCoast Bio and Diaclone, is a leading global supplier of critical raw materials used for in vitro diagnostics (IVD). Medix recently acquired Diaclone, a prominent provider of monoclonal antibodies in the areas of inflammation, oncology, and immunology. At MEDICA 2021, Medix showcased its wide portfolio of monoclonal antibodies, antigens for immunoassay materials, molecular diagnostics reagents, enzymes for clinical chemistry controls, and biochemicals and biological.

Medix highlighted its range of quality reagents offered through MedixMDx in combination with a host of custom services to provide IVD kit manufacturers, labs and research institutions with the tailored support they need from proof-of-concept right through to release for sale. In addition to highlighting its wide range of high-quality reagents and master mixes designed to shorten development timelines and work with various assay technologies, Medix also threw light on its technical support provided to clients as they develop their assays as well as contract manufacturing services.

Medix highlighted its broad range of platform-agnostic reagents, including enzymes, nucleic acid extraction products, buffers and as well as consumables. The company showcased its range of enzymes, ready mixes, controls, clinical specimens and general reagents in the areas of PCR/qPCR, isothermal nucleic acid amplification technologies (iNAAT), Next generation Sequencing (NGS).

Related Links:
Medix Biochemica 


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Food Allergy Screening ELISA Kit
Allerquant 14G B ELISA
POC Immunoassay Analyzer
Procise DX
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: A large, international study led by City of Hope found that the new, investigational liquid biopsy, called PANXEON, was highly sensitive in detecting stage 1 and 2 pancreatic cancer and had a low rate of false positives. The test was also able to identify high-grade dysplasia, a precancerous condition of the pancreas, potentially enabling intervention before cancer develops. (Photo courtesy of City of Hope)

Multi-Biomarker Blood Test Shows Promise for Early Pancreatic Cancer Detection

Pancreatic cancer has the lowest survival rates of any cancer, with only 14% of patients alive five years after diagnosis. The disease is typically discovered after it has spread, and an estimated 90%... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Technology

view channel
Image: Graphical Abstract (Wenjie Zhang, Zeyu Luo, Kaijie Liu, et al. Science Bulletin, 2026. doi:10.1016/j.scib.2026.09.016)

Multimodal AI Framework Aims to Guide Cancer Immunotherapy Decisions

Cancer immunotherapy has reshaped oncology, but heterogeneous responses and immune-related toxicities continue to complicate routine decision-making. Standard biomarkers, including programmed death-ligand... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.